BR112012004237A8 - métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10) - Google Patents

métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)

Info

Publication number
BR112012004237A8
BR112012004237A8 BR112012004237A BR112012004237A BR112012004237A8 BR 112012004237 A8 BR112012004237 A8 BR 112012004237A8 BR 112012004237 A BR112012004237 A BR 112012004237A BR 112012004237 A BR112012004237 A BR 112012004237A BR 112012004237 A8 BR112012004237 A8 BR 112012004237A8
Authority
BR
Brazil
Prior art keywords
alterator
epimetabolic
coenzyme
methods
treating sarcoma
Prior art date
Application number
BR112012004237A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012004237A2 (pt
Inventor
John Patrick Mccook
Niven Rajin Narain
Rangaprasad Sarangarajan
Original Assignee
Berg Pharma Llc
Cytotech Labs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Pharma Llc, Cytotech Labs Llc filed Critical Berg Pharma Llc
Publication of BR112012004237A2 publication Critical patent/BR112012004237A2/pt
Publication of BR112012004237A8 publication Critical patent/BR112012004237A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
BR112012004237A 2009-08-25 2010-08-25 métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10) BR112012004237A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23684509P 2009-08-25 2009-08-25
PCT/US2010/046711 WO2011031503A2 (en) 2009-08-25 2010-08-25 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)

Publications (2)

Publication Number Publication Date
BR112012004237A2 BR112012004237A2 (pt) 2016-04-05
BR112012004237A8 true BR112012004237A8 (pt) 2016-10-04

Family

ID=43730801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004237A BR112012004237A8 (pt) 2009-08-25 2010-08-25 métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)

Country Status (15)

Country Link
US (2) US20110064747A1 (enExample)
EP (1) EP2470169A4 (enExample)
JP (2) JP6159085B2 (enExample)
KR (1) KR101572463B1 (enExample)
CN (2) CN102548549A (enExample)
AU (2) AU2010292532A1 (enExample)
BR (1) BR112012004237A8 (enExample)
CA (1) CA2772068C (enExample)
CR (1) CR20120120A (enExample)
EA (1) EA201270325A1 (enExample)
IL (1) IL218306B (enExample)
IN (1) IN2012DN01911A (enExample)
MX (1) MX2012002208A (enExample)
SG (2) SG178547A1 (enExample)
WO (1) WO2011031503A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120034649A (ko) * 2009-05-11 2012-04-12 버그 바이오시스템즈, 엘엘씨 환경대사적 전환인자(조효소 q10)를 사용한 질환의 치료 방법
EP2694463B8 (en) 2011-04-04 2019-10-09 Berg LLC Treating central nervous system tumors with coenzyme q10
WO2014059008A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
CN104703585A (zh) 2012-10-09 2015-06-10 宝洁公司 鉴定协同化妆品组合的方法
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
MX380565B (es) 2013-04-08 2025-03-12 Berg Llc Terapias combinadas de coenzima q10 para el tratamiento de cáncer.
MX381399B (es) 2013-09-04 2025-03-12 Berg Llc Formulaciones de coenzima q10 y métodos de uso.
US10627392B2 (en) 2014-06-17 2020-04-21 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
US10527620B2 (en) * 2014-07-07 2020-01-07 Allergan, Inc. Method of detecting cleaved SNAP25 in tissue samples
CN105044360A (zh) * 2015-07-22 2015-11-11 浙江大学医学院附属邵逸夫医院 Rbp4作为结直肠癌血清标记物的应用及诊断试剂盒
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN106053813A (zh) * 2016-06-25 2016-10-26 林森 一种检测鼻咽癌pdk1表达量的免疫组化试剂盒及其应用
CN106947010B (zh) * 2017-04-06 2018-12-11 哈尔滨工业大学 一种利用光引发raft聚合原位诱导自组装制备蛋白质基纳米粒子的方法
KR102682716B1 (ko) * 2017-05-17 2024-07-08 비피지바이오, 인크. 수포성 표피박리증의 치료 및 예방에서 조효소 q10 제형의 용도
CN107226862A (zh) * 2017-05-27 2017-10-03 南京川博生物技术有限公司 特异性人ews‑fli1融合蛋白抗体的制备方法及在制备尤文肉瘤诊断抗体试剂的应用
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
US20230080670A1 (en) * 2019-04-05 2023-03-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating tumors using transcription inhibition and dna damage
US20240141352A1 (en) * 2021-03-05 2024-05-02 University Of Central Florida Research Foundation, Inc. Chaperonin-containing tcp-1 inhibitors for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
JP2006345701A (ja) * 2003-07-01 2006-12-28 Taisho Pharmaceut Co Ltd タキサン類応答性の判別方法
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
BRPI0507039A8 (pt) * 2004-01-22 2018-12-18 Univ Miami composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit
EP1756306A2 (en) * 2004-05-14 2007-02-28 Ludwig Institute For Cancer Research Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib
WO2006125143A2 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007026895A1 (ja) * 2005-09-02 2007-03-08 Toray Industries, Inc. 尿路上皮ガンの検出用キットおよび方法
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8211634B2 (en) * 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8030013B2 (en) * 2006-04-14 2011-10-04 Mount Sinai School Of Medicine Methods and compositions for the diagnosis for early hepatocellular carcinoma
JP5147852B2 (ja) * 2007-10-18 2013-02-20 株式会社メディカル・プロテオスコープ 手術後の予後を推定する方法及び診断キット

Also Published As

Publication number Publication date
CA2772068C (en) 2017-03-21
CN102548549A (zh) 2012-07-04
WO2011031503A3 (en) 2011-07-21
WO2011031503A2 (en) 2011-03-17
EA201270325A1 (ru) 2012-11-30
EP2470169A2 (en) 2012-07-04
US20130266557A1 (en) 2013-10-10
EP2470169A4 (en) 2013-03-13
AU2010292532A1 (en) 2012-04-05
CA2772068A1 (en) 2011-03-17
JP6159085B2 (ja) 2017-07-05
AU2016277749A1 (en) 2017-02-02
MX2012002208A (es) 2012-06-12
BR112012004237A2 (pt) 2016-04-05
IN2012DN01911A (enExample) 2015-07-24
CN108245497A (zh) 2018-07-06
CR20120120A (es) 2012-07-04
US20110064747A1 (en) 2011-03-17
SG178547A1 (en) 2012-03-29
JP2016136938A (ja) 2016-08-04
KR101572463B1 (ko) 2015-11-27
JP2013503175A (ja) 2013-01-31
IL218306A0 (en) 2012-04-30
SG10201405069QA (en) 2014-10-30
IL218306B (en) 2018-05-31
KR20120050495A (ko) 2012-05-18

Similar Documents

Publication Publication Date Title
BR112012004237A8 (pt) métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)
BRPI1010827A2 (pt) métodos para tratamento de doença usando um transferidor epimetabólico (coenzima q10)
BR112012006989A2 (pt) método para usar um dispositivo de entretenimento
PT2773748T (pt) Neurónios dopaminérgicos (da) do mesencéfalo para enxerto
HRP20181713T1 (hr) Viličasta stezaljka automata za gazirana pića
BRPI1013219A2 (pt) método para o alvejamento-branqueamento enzimático têxtil
BRPI0911077A2 (pt) método para tratamento de biomassa
GB201119111D0 (en) Illumination apparatus
SMT202000232T1 (it) Metodi per trattare dlbcl
EP2791103A4 (en) BETULINDERIVATE
PL3339052T3 (pl) Sposób dekorowania powierzchni
BR112014007654A2 (pt) inibidores de lrrk2 quinase macrocíclicos.
BR112013023553A2 (pt) aparelho, método e módulo de mecanismo de iluminação
CO7061068A2 (es) Derivados de polimixina
BR112013028128A2 (pt) composição de polímero para dispositivos elétricos
BR112013024378A2 (pt) novos derivados de pirimidina
EP2646899A4 (en) SYSTEM FOR INTERNETABLE PRINTING
EP2791653A4 (en) PROCESS FOR OPTIMIZED SCATTEROMETRY
BR112013028282A2 (pt) composição de polímero para dispositivos elétricos
EE00888U1 (et) Kandeseina asendamise meetod
EP2788701B8 (de) Verfahren zum trocknen von schlamm
EP2664845A4 (de) Beleuchtungsvorrichtung
EP2751084A4 (en) YRIMIDINCARBOXAMIDDERIVATE
BRPI1008016A2 (pt) método para o tratamento de águas residuais
EP2453746A4 (en) TAZAROTENDERIVATE

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BERG PHARMA LLC (US)

B25D Requested change of name of applicant approved

Owner name: BERG LLC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2476 DE 19-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.